Table III.

Urinary procarcinogen biomarker levels in smokers, commercial smokeless tobacco users and iqmik users

	Plasma NMR strata			CYP2A6 genotypes
	Slower	Faster	P	Reduced	Normal	P
Smokers (n = 141)	n = 71	n = 70		n = 62	n = 79
NNAL (pmol/mg Cre), mean (SD)	1.1 (0.8)	1.4 (1.2)	0.52	1.1 (0.8)	1.3 (1.2)	0.45
NNN (pmol/mg Cre), mean (SD)	0.182 (0.390)	0.110 (0.200)	0.57	0.230 (0.450)	0.083 (0.093)	0.05
Commercial smokeless tobacco users (n = 73)	n = 37	n = 36		n = 34	n = 39
NNAL (pmol/mg Cre), mean (SD)	4.5 (3.6)	7.3 (6.0)	0.01	4.6 (4.0)	7.1 (5.6)	0.006
NNN (pmol/mg Cre), mean (SD)	0.126 (0.114)	0.107 (0.088)	0.68	0.119 (0.119)	0.113 (0.084)	0.67
Iqmik users (n = 20)	n = 10	n = 10		n = 9	n = 11
NNAL (pmol/mg Cre), mean (SD)	0.8 (0.6)	0.7 (0.3)	0.65	0.9 (0.51)	0.7 (0.42)	0.34
NNN (pmol/mg Cre), mean (SD)	0.756 (1.95)	0.154 (0.195)	0.71	0.205 (0.211)	0.660 (1.87)	0.52

Bold values indicate statistically significant differences between the groups by Wilcoxon’s test.